Zur Kurzanzeige

2021-03-24Zeitschriftenartikel DOI: 10.25646/8647
Amantadine Inhibits SARS-CoV-2 In Vitro
dc.contributor.authorFInk, Klaus
dc.contributor.authorNitsche, Andreas
dc.contributor.authorNeumann, Markus
dc.contributor.authorGrossegesse, Marica
dc.contributor.authorEisele, Karl-Heinz
dc.contributor.authorDanysz, Wojciech
dc.date.accessioned2021-06-14T08:44:45Z
dc.date.available2021-06-14T08:44:45Z
dc.date.issued2021-03-24none
dc.identifier.other10.3390/v13040539
dc.identifier.urihttp://edoc.rki.de/176904/8368
dc.description.abstractSince the SARS-CoV-2 pandemic started in late 2019, the search for protective vaccines and for drug treatments has become mandatory to fight the global health emergency. Travel restrictions,social distancing, and face masks are suitable counter measures, but may not bring the pandemic under control because people will inadvertently or at a certain degree of restriction severity or duration become incompliant with the regulations. Even if vaccines are approved, the need for antiviral agents against SARS-CoV-2 will persist. However, unequivocal evidence for efficacy againstSARS-CoV-2 has not been demonstrated for any of the repurposed antiviral drugs so far. Amantadinewas approved as an antiviral drug against influenza A, and antiviral activity against SARS-CoV-2has been reasoned by analogy but without data. We tested the efficacy of amantadine in vitro in Vero E6 cells infected with SARS-CoV-2. Indeed, amantadine inhibited SARS-CoV-2 replication in two separate experiments with IC50 concentrations between 83 and 119μM. Although these IC50 concentrations are above therapeutic amantadine levels after systemic administration, topical admin-istration by inhalation or intranasal instillation may result in sufficient amantadine concentration in the airway epithelium without high systemic exposure. However, further studies in other models are needed to prove this hypothesis.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectamantadineeng
dc.subjectantiviral drugseng
dc.subjectCovid-19eng
dc.subjectSARS-CoV-2eng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleAmantadine Inhibits SARS-CoV-2 In Vitronone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/8368-6
dc.identifier.doihttp://dx.doi.org/10.25646/8647
dc.type.versionpublishedVersionnone
local.edoc.container-titlevirusesnone
local.edoc.container-issn1999-4915none
local.edoc.pages10none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.mdpi.com/1999-4915/13/4/539none
local.edoc.container-publisher-nameMDPInone
local.edoc.container-volume13none
local.edoc.container-issue4none
local.edoc.container-periodicalpart-titleVaccines and Therapeutics against Coronavirusesnone
local.edoc.rki-departmentZentrum für Biologische Gefahren und Spezielle Pathogenenone
dc.description.versionPeer Reviewednone

Zur Kurzanzeige